FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer On May 8, 2025, the Food and Drug Administration granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem, Inc.) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. FDA approves belzutifan for pheochromocytoma or paraganglioma On May 14, 2025, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). This represents the first FDA approval of an oral therapy for PPGL. FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression On May 14, 2025, the Food and Drug Administration granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis, AbbVie Inc.), a c-Met-directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy. FDA approves retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal On May 15, 2025, the Food and Drug Administration approved retifanlimab-dlwr (Zynyz, Incyte Corporation) with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). The FDA also approved retifanlimab-dlwr, as a single agent, for adults with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.

    Data from the POD1UM-303/InterAACT2 trial support the approval of retifanlimab/chemotherapy for patients with squamous cell carcinoma of the anal canal.

Treatment Advances and Management of ES-SCLC

  Featured Video

 

                                                         FACULTY
 

  Presented by:   Learning Objectives:
Following this activity, participants should be able to:     Fee Information:
There is no fee to attend this activity.

Accreditation:
CE credit for this activity is available for the oncology care team including physicians, nurses, pharmacists, PAs, and case managers. Upcoming Tumor Board Webinar: Recorded Presentations: 
Access recorded presentations from this series. Supporters:
This activity is supported by educational grants from AstraZeneca; Coherus BioSciences; Eisai Inc.; Genentech, a member of the Roche Group; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Novartis; and Sanofi. This activity is supported by independent educational grants from Daiichi Sankyo and Merck & Co., Inc., Rahway, NJ, USA. This is activity is supported by independent medical education grants from AbbVie and GSK.

時        間：114年4月12日(六) 14:00~17:00 (視訊)
地        點:   臺灣血液腫瘤藥學會YouTube頻道線上
主辦單位：臺灣血液腫瘤藥學會
協辦單位：友華生技醫藥股份有限公司

注意事項：
1.本研討會採用GOOGLE簽到，須完成簽到、課後滿意度及簽退，方能獲得學分。
2.報名開始日：即日起至4月12日
3.若有相關課程問題，請洽研討會聯絡人任冠臻小姐。E-mail: twhopa@gmail.com


---請使用海報連結掃碼填單報名---

  Featured Video